New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity

Data ReadoutpositiveTaltzZepboundPositive

AI Analysis

Summary

Eli Lilly announced Phase 3b data from the TOGETHER-PsO study showing that combination treatment with Taltz and Zepbound produced broader biomarker changes versus Taltz alone in adults with psoriasis and obesity, with effects observed by Week 12.

Clinical Trial Data

Phase

Outcome Details

Phase 3b exploratory data showed broader biomarker changes with Taltz and Zepbound combination versus Taltz alone as early as Week 12 in TOGETHER-PsO study

Importance:7/10

Sentiment:

0.70

Phase 3b datacombination therapypsoriasisobesitybiomarker analysisimmunometabolism

Related Companies

$LLY

Read the original article

Published by PR Newswire Biotech on October 9, 2026 10:45 AM

Read Original